Stanford Neuro-Immuno-Oncology Program Clinical Trials

  • – Stanford Cancer Institute

    Groundbreaking Stanford cancer treatment receives important FDA designation

    A promising Stanford Medicine treatment for deadly pediatric brain and spinal cord cancers received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration to expedite the approval process. By expediting approval, more children will be able to benefit from the treatment sooner.

GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma (DMG)
Sponsor: Crystal Mackall, MD
Principal Investigator: Michelle Monje, MD, PhD
Description: This is an open label, non-randomized, single site Phase 1 study to test the manufacturing feasibility and safety of administration of GD2 CAR T into the central nervous system of pediatric and adult subjects with H3K27M-mutant diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG) using a rolling-6 escalation design
ClinicalTrials.gov Identifier: NCT04196413
Study Status: Enrolling
Contact: GD2CART@stanfordchildrens.org or 650-497-7533

B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme
Sponsor: Crystal Mackall, MD
Principal Investigator: Reena Thomas, MD, PhD
Description: This is an open label, non-randomized, single site Phase I study to test the manufacturing feasibility and safety of locoregional (LR) administration of B7-H3CART into the central nervous system of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design
ClinicalTrials.gov Identifier: NCT05474378
Study Status: Enrolling
Contact: lewis.naya@stanford.edu or 650-725-0379